Psychedelics Archives - InvestorWire (IW)

Tuesday Jul 20, 2021 - 9:30 am

Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) Announces New Board Appointment

Former head of psychiatry products at FDA joins Cybin team.Laughren will help company plot its regulatory pathway as it studies and develops psychedelic medicines. Cybin (NEO: CYBN) (OTCQB: CLXPF), a biotechnology company focused on progressing psychedelic therapeutics, is making strategic moves as it progresses with pre-clinical and clinical trials. One of those steps includes the company’s recent announcement that Thomas Laughren is joining Cybin’s clinical…

Monday Jul 19, 2021 - 9:30 am

Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) Acquisition Leads to Milestone Achievement, Positive Pre-Clinical Results

CYBN subsidiary Adelia Therapeutics has reached earn-out milestones.Adelia’s earn-out milestones contributed to positive preclinical results with multiple proprietary psychedelic molecules.Cybin’s development of these compounds differentiates it from companies focused on naturally occurring psychedelic compounds. Cybin (NEO: CYBN) (OTCQB: CLXPF), a biotechnology company focused on progressing psychedelic therapeutics, has announced that earn-out milestones have been reached by its wholly controlled subsidiary Adelia Therapeutics Inc. These milestones,…

Monday Jul 12, 2021 - 12:31 pm

XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Marks Major Milestone for its Rapid Point-Of-Care Diagnostic Business Strategy

XPhyto began delivery of approximately 1,000 Covid-ID Lab test kits in BerlinThis marks a significant achievement commercially, as well as for the company’s point-of-care diagnostic business strategyThe lab tests are designed to offer reliable Covid-19 test results in under 25 minutesXPhyto plans to capitalize on the rapid test market, projected to reach $39.1 billion by 2023 For the week starting June 27, 2021, XPhyto Therapeutics…

Thursday Jul 08, 2021 - 1:03 pm

Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Leveraging Similar Strategy as Leading Cannabis-Derived Compound Pharmaceutical Company

Jazz Pharmaceuticals’ acquisition of GW Pharma for $7.2 billion in February 2021 shows the massive potential of the drug development industry from naturally-derived compoundsTryp Therapeutics is following in the footsteps of GW with its innovative drug pipeline and the development of psilocybin-based compounds for the treatment of diseases with high unmet medical needsIt is one of only a handful of companies moving into Phase 2a…

Tuesday Jul 06, 2021 - 9:15 am

Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) Featured in Stifel Report; Price Target Raised by C$12, Rated as Spec Buy

CYBN continues to demonstrate good progress with its preclinical activities on its novel drug programs, report observedStifel also notes selecting indications with large patient pools, an understated market size, and potential for multiple synergies across development and distributionReport incorporates both CYB001 and CYB004 into valuation As Cybin (NEO: CYBN) (OTCQB: CLXPF), a biotechnology company focused on progressing psychedelic therapeutics, continues to develop its multimolecule strategy,…

Friday Jul 02, 2021 - 10:20 am

Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) to Share its Drug Development Pipeline and the Company’s Progress in the Psych Investor Summit

Tryp Therapeutics will be participating in the second global Psych Investor Summit: Research and DevelopmentThe virtual presentation is scheduled for July 7 from 11:50 a.m. to 12:50 p.m. EDTIt will focus on the psychedelics industry, showcasing the latest research and development within the sectorMr. Greg McKee, Chairman and CEO of Tryp Therapeutics, will share information on the company, along with its drug development pipeline In…

Wednesday Jun 30, 2021 - 2:06 pm

XPhyto Therapeutics Corp.’s (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Mescaline Program for Psychedelic Therapies is on Track

XPhyto Therapeutics Corp (OTCQB: XPHYF) announced its GMP mescaline synthesis program is “on schedule”The program, which started in early 2021, is slated for completion in late Q3 2021The first initial production batches were completed successfully, marking a significant milestone for the programMescaline will form a critical component in XPhyto’s psychedelic medicine program and work towards providing a foundation for its drug formulation and clinical validation…

Friday Jun 25, 2021 - 11:42 am

Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Discusses Its Vision for Addressing Patient Needs

In 2021, Tryp Therapeutics plans on expanding its academic collaborationsIt also plans to initiate Phase 2a clinical studies for its synthetic psilocybin drug product as a way to determine efficacy in patient populationsTryp Therapeutics is constantly working on identifying alternative and better ways to control doses and control the patient experience in their dissociative state, mainly through innovations in drug formulation and deliveryA primary objective…

Thursday Jun 24, 2021 - 3:21 pm

Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) Targets Anxiety Disorders in Focus of Proprietary Psychedelic Treatments

Decision represents opportunity to help millions suffering from social, generalized anxiety disordersGlobal markets will reach an estimated $4 billion this year, with significant growth projected looking forwardWHO estimates that 1 in 13 adults globally suffer from anxiety; treatment options have slow onset, undesirable side effects Cybin (NEO: CYBN) (OTCQB: CLXPF), a biotechnology company focused on progressing psychedelic therapeutics, has identified social anxiety disorder, or SAD,…

Thursday Jun 17, 2021 - 10:53 am

Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) Announces First-Ever Trial to Treat COVID-19 Frontline Clinicians, Unveils EMBARK Model

The study will examine treating symptoms of depression, anxiety, burnout and post-traumatic stressEMBARK is groundbreaking psychotherapy model that integrates leading clinical approaches to promote supportive healing with psychedelic medicineCybin considers it an honor, duty to support healing processes of doctors, nurses and healthcare professionals, says CEO In the first-ever study of its kind, Cybin (NEO: CYBN) (OTCQB: CLXPF), a biotechnology company focused on progressing psychedelic…

Thursday Jun 17, 2021 - 9:00 am

Pure Extracts Technologies Corp. (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ) Commences Production of 1 Gram FSO Vape Cartridges for Canadian Retail Market

Pure Extracts working on innovative, larger capacity cartridge for vape products, destined for Canadian retail marketCartridges to be produced by global manufacturer, will be filled with selection of Pure Extracts’ 30+ proprietary cannabis FSO formulationsMove towards larger cartridges follows careful assessment of underlying consumer trends by the Company, finding demand for higher capacity vape cartridges to be particularly strong within provincial markets Pure Extracts Technologies…

Wednesday Jun 16, 2021 - 10:38 am

Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Presentation to Provide Overview of Psychedelic Drug Candidate Program at Ladenburg Thalmann Healthcare Conference

Tryp Therapeutics is a development-stage pharmaceutical company dedicated to finding novel bioscience solutions for conditions with unmet needsThe company’s executive team will present an overview of its Psilocybin-For-Neuropsychiatric Disorders (“PFN”) program, in response to conditions such as fibromyalgia, at next month’s Ladenburg Thalmann Healthcare ConferenceTryp’s synthetic psychedelic drug candidate will be further developed in an upcoming phase 2a clinical study in partnership with pediatric eating…

Tuesday Jun 15, 2021 - 1:14 pm

XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Commences Sale of Rapid COVID-19 RT-PCR Test Kits in Germany Amid Potential Surge in Demand

XPhyto’s distribution, storage, and logistics partner, Max Pharma GmbH, began the sale and delivery of its rapid test kits (Covid-ID Labs) in Germany on May 25Max Pharma will sell Covid-ID Labs at volume-dependent pricing comparable to other COVID-19 PCR test products on the marketThe announcement comes as Germany reopens, meaning XPhyto is likely to benefit from a raft of regulatory requirements instituted by the government,…

Tuesday Jun 15, 2021 - 9:00 am

Pure Extracts Technologies Corp. (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ) Expands Sales into Public Sector with BC Liquor Distribution Board Purchase

PULL secures edible cannabis gummies order from British Columbia Liquor Distribution BranchPULL’s cannabis gummies produced in blister packs using proprietary manufacturing system licensed from US-based Taste-T, LLC SKUs include 10 mg THC options in Fire Burst, Strawberry, and Mango flavors, three additional non-THC SKUs currently in developmentGlobal CBD gummies market estimated at $1.6 billion in 2020, 30.7% CAGR from 2021 to 2028 Pure Extracts Technologies (CSE:…

Friday Jun 11, 2021 - 9:00 am

Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) to Sponsor Kernel Flow, Ketamine Feasibility Study

Feasibility study is designed to measure ketamine’s psychedelic effect on cerebral cortex hemodynamicsCybin, Kernel working together to leverage proprietary Kernel Flow device for psychedelic-based studies and clinical trialsKetamine is a dissociative injected anesthetic that blocks sensory perception Cybin (NEO: CYBN) (OTCQB: CLXPF) has announced a key step forward in its focus on progressing psychedelic therapeutics. The company will be sponsoring a feasibility study of the…

Thursday Jun 10, 2021 - 10:44 am

Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) to Present at H.C. Wainwright’s Upcoming Virtual Psychedelics Conference

Tryp Therapeutics’ Chairman and CEO Greg McKee will present at the virtual Psychedelics in Psychiatry and Beyond Conference planned for Thursday, June 17, 2021As part of his presentation, McKee will discuss Tryp’s business and its pipeline, which includes its proprietary psilocybin-centered drug development programTryp will present alongside other pharmaceutical companies leading research in psychedelic-assisted therapeutics Psychedelics have increasingly drawn the attention of different players and…

Wednesday Jun 09, 2021 - 9:00 am

Pure Extracts Technologies Corp. (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ) Inks White Label Agreement as Strategic Planning Pays Off

White label agreement with FLO Brands outlines launch of cannabis vape product linePULL beginning to execute strategy to get white label products into provincial dispensaries, drive up to $3 million of annual revenueNikolaevsky reports that “white labeling has also begun to build momentum and gain sales traction for us” Pure Extracts Technologies (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ), a plant-based extraction company focused on cannabis,…

Friday Jun 04, 2021 - 9:30 am

Pure Extracts Technologies Corp. (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ) Opens Direct-To-Consumer Amazon Store under Pure Mushrooms Brand

PULL subsidiary Pure Mushrooms Corp. opens direct-to-consumer e-Commerce store on Amazon platformStore features Reishi, Maitake formulations with plans to add Lion’s Mane in summer 2021Global functional mushroom market valued at $25.4 billion in 2020, expected CAGR of 8.44% from 2021-2026Company expands psychedelic vertical through letter of intent with Psyence Group to co-produce psychedelic mushroom-based psilocybin formulations Pure Extracts Technologies (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ),…

Thursday Jun 03, 2021 - 10:24 am

Pure Extracts Technologies Corp. (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ) Notes Impressive Advancement in Cannabis, Functional Mushrooms, Psilocybin Spaces

Pure Extracts’ BC facility is fully operational, ready to meet increasing demand for cannabis-based gummies, vapes, white label productsCompany’s involvement in functional, psychoactive mushrooms space is also gaining steamPure Extracts’ current R&D focus is on psychoactive mushroom compounds Although the global pandemic extended its sales cycle, Pure Extracts Technologies (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ) is seeing interest from producers and brands looking for new opportunities and…

Thursday Jun 03, 2021 - 9:00 am

Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Targets Academic Collaborations to Advance Research on Largely Ignored Indications for Psilocybin

Psychedelics have been on the receiving end of groundbreaking research, which have greatly influenced the medical acceptance of the compoundsPharmaceutical developer Tryp Therapeutics is looking to use existing preclinical and clinical data to proceed directly to Phase 2a clinical trialsThe company intends to contribute to the growing body of research through academic collaborations with leading American institutions The research will focus on indications that other pharmaceutical…

Wednesday Jun 02, 2021 - 9:15 am

XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Beginning 2021 Strong with New Drugs and Life Sciences Advancements

Promising results have been recorded in the first pilot study of a Rotigotine skin patch for Parkinson’s patientsWholly owned subsidiary Vektor is reaching a major milestone in the development of Rotigotine with the potential for a pivotal human trialThe company is planning the construction of a new lab and manufacturing space up to 32,000 square feet in Biberach, GermanyPilot project involving rapid COVID-19 PCR tests…

Friday May 28, 2021 - 11:33 am

Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Building Psychedelic Medicine Program on Foundation of Strong Leadership, Pharmaceutical Alliances

Pharmaceutical developer Tryp Therapeutics is focused on producing novel bioscience solutions for conditions with unmet needsTryp’s current flagship program involves development of a synthetic psychedelic drug candidate for treating specific pain and eating disorder indicationsThe company expects to begin manufacturing its initial oral psilocybin formulation in September 2021Tryp’s scientific and executive team has decades of experience in large pharma, emerging pharma, drug approvals, psychedelics and…

Wednesday May 26, 2021 - 9:00 am

Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) Files Patent Designed to Bolster IP Psychedelic Molecule, Delivery Mechanism Portfolio

Company files 12th patent to strengthen proprietary IP programCybin believes treatments can decrease costs, increase access to important therapeuticsPatent provides wide range of benefits in Cybin’s four drug candidate program Cybin (NEO: CYBN) (OTCQB: CLXPF) has filed a new provisional patent application designed to strengthen the company’s ongoing drug candidate programs (https://ibn.fm/9V5sv). Cybin, a biotechnology company focused on progressing psychedelic therapeutics, is focused on expanding…

Monday May 24, 2021 - 1:50 pm

Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Upcoming Drug Candidate Trial Rides Swell of Groundbreaking Psychedelic Medicine Efforts

Tryp Therapeutics is a pharmaceutical company focused on developing new potential treatments for medical conditions with unmet needsThe company’s current lead candidates for drug development are a synthetic psychedelic for treating fibromyalgia and eating disordersTryp’s efforts to develop a psychedelic drug candidate are part of a broader scientific movement to use various mind-altering drugs to treat select neurological conditions when paired with the care of…

Tuesday May 18, 2021 - 9:15 am

XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Targets Potential Expansion of Rapid COVID-19 Test Kit Distribution with Delivery of 2,000 Units to Israel

XPhyto recently delivered 2,000 of its rapid Covid-ID Lab test kits to an established Israeli distributor for clinical evaluation by the Ministry of HealthThe delivery, which marks entry into the Middle East, follows the approval of the test kits in EuropeIn an earlier interview, CEO Hugh Rogers had noted that XPhyto was looking to expand distribution to various markets, including the Middle East In an…

Friday May 14, 2021 - 12:07 pm

Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) Maintains Buy Rating in Recent Equity Update

April analyst reports all point to a bright future for Cybin“CYBN is a true multi-molecule company that's not being reflected in its valuation,” reports Stifel“With a relatively small 5% penetration, Cybin could achieve ~$8B in sales in the U.S. and EU5 combined,” notes Roth A series of recent analyst reports bodes well for Cybin (NEO: CYBN) (OTCQB: CLXPF), a leading biotech company focused on progressing…

Thursday May 13, 2021 - 12:06 pm

Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Builds Alliances Ahead of Psychedelic Drug Trial for Eating Disorders

Orphan-stage pharmaceutical innovator Tryp Therapeutics is dedicated to developing novel therapies for medical conditions with unmet needsTryp’s embrace of psychedelic drug potential is demonstrated in its advancing clinical trials seeking an answer to eating disorders such as binge eating and hyperphagiaThe company is also developing a clinical trial to address the needs of fibromyalgia patients who often rely on opioids to relieve their symptomsTryp has…

Tuesday May 11, 2021 - 1:18 pm

Business Booming in April: Pure Extracts Technologies Corp. (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ) Lands Tolling Agreement to Extract CBD from 500 Kg Hemp Biomass

CBD-infused products market is expected to grow 48.1% annually to reach $165.7 billion by 2027Pure Extracts Technologies’ subsidiary recently began production of goods expected to generate approximately $950,000 in revenueNew tolling agreement is for extraction of 80-85% pure CBD distillate from an initial 500 kilograms (~1,102 pounds) of hemp biomass Any industry forecast for double-digit growth is one worth keeping an eye on. When experts…

Monday May 10, 2021 - 12:19 pm

Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) Looks to New Senior Management with Expertise in Development, Clinical Capabilities

Company committed to building presence in U.S. and Europe to advance mission of improving mental health careNew appointments will strengthen Cybin’s development and clinical operations globally, solidify position within the industryNew leaders bring broad experience, deep insight to their new roles Cybin (NEO: CYBN) (OTCQB: CLXPF), a leading biotech company focused on progressing psychedelic therapeutics, recently made key senior-management changes designed to provide the company…

Friday May 07, 2021 - 1:47 pm

Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Investigates Alleviating Neurological Disorders with Psychedelics

Tryp Therapeutics is a pharmaceutical developer working to produce novel bioscience solutions, including a synthetic psychedelic drug candidate for treating some chronic pain and eating disordersTryp CEO Greg McKee appeared on the Entrepreneur Magazine podcast “Action and Ambition” earlier this month to discuss lessons learned on his road to success and to highlight the company’s purpose in developing treatments for helping people be more wholePsychedelic…

Wednesday May 05, 2021 - 12:07 pm

Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) Signs Drug-Development Agreement, One Step Closer to Effective Psychiatric Disorder Treatment

Agreement calls for Cybin, Catalent to work together to develop novel therapy for treatment-resistant psychiatric disordersCybin looking to identify fast-acting, shorter-duration formulations of CYB003Delivering CYB003 through Catalent ODT could provide significant benefits Cybin (NEO: CYBN) (OTCQB: CLXPF), a biotechnology company focused on progressing psychedelic therapeutics, has inked a drug-development agreement with Catalent Inc. (NYSE: CTLT), a leading global provider of advanced delivery technologies, development, and…

Tuesday May 04, 2021 - 2:27 pm

XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Inks Distribution Agreement for Rapid COVID-19 Test Kits; Expands Commercial Leadership Team in Anticipation of Strong, Sustainable Sales

XPhyto Therapeutics Corp. recently announced it has entered into a distribution, storage and logistics agreement with a German distributor with an established network throughout GermanyGermany holds promise due to regulations requiring mandatory weekly testing for its citizens; this has the possibility of ramping up salesAnticipating the increase in sales and distribution, XPhyto expanded its commercial leadership team by bringing on board Mr. Wolfgang Probst and…

Tuesday May 04, 2021 - 11:48 am

Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Leading Charge in Developing Psychedelic Medicines for Treating Rare Eating Disorders

Pharmaceutical developer Tryp Therapeutics is targeting orphan disorders with novel medicinal solutionsThe company’s initial candidates seeking regulatory approval are a psilocybin compound for treating fibromyalgia, eating disorders and chronic pain conditions, as well as a tumor-inhibiting drug for treating soft tissue sarcomasTryp has partnered with the University of Florida to conduct a Phase 2a clinical trial for eating disorders using Tryp's psilocybin product Following a…

Monday May 03, 2021 - 1:07 pm

Pure Extracts Technologies Corp. (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ) Makes Headway into Canadian Cannabis Vape Market with 25,000 Unit Production Run

Production underway for 25,000 vape cartridges using PULL full spectrum oil formulations, including Super Lemon Haze, Grand Daddy Purple and Girl Scout Cookies/GSKCompany estimates retail sales revenue for this production run will be approximately $750,00060% of respondents in StatCan’s Canadian 2020 Cannabis Survey that used vaporizer for cannabis in the last 12 months used oil/extracts “Cannabis 2.0,” the colloquial term for legalization of cannabis derivatives…

Friday Apr 30, 2021 - 1:53 pm

Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Is ‘One to Watch’

Tryp Therapeutics is a pharmaceutical company with a focus on developing clinical-stage compounds for diseases with high unmet medical needs through accelerated regulatory pathwaysThe company currently has two drug candidates in development: TRP-8802 (targeting fibromyalgia, eating disorders and chronic pain conditions); and TRP-1001 (targeting soft tissue sarcomas)Through its PFN(TM) program, the company is focused on developing psilocybin-based drug therapies for certain neuropsychiatric disorders that offer…

Wednesday Apr 28, 2021 - 12:04 pm

Pure Extracts Technologies Corp. (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ) Retail Business to Bloom This Spring With Production of 50,000 Blister Packs

PULL starts production of roughly 50,000 blister pack gummies using Taste-T LLC’s successful proprietary manufacturing systemGlobal CBD gummies market size estimated to grow at CAGR of 31.9% until 2025 PULL estimates $200,000 in revenue from initial batch, plans to produce three additional non-THC SKUs with varying levels of ultra-high potency CBD Pure Extracts Technologies (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ), a plant-based extraction company focused on…

Friday Apr 16, 2021 - 12:16 pm

Largely Untapped Market for Hallucinogenic Draws Attention of Researchers at XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT)

XPhyto Therapeutics Corp., a life sciences technology accelerator, is looking for ways to turn promising psychedelics into therapeutic pharmaceutical drugs, and recently added mescaline to its study profileMescaline is illegal under U.S. federal law, but some state-centric efforts to legalize or decriminalize the hallucinogenic have launched in a manner similar to the populace effort that produced a wave of cannabis product legalizationMescaline has historically defied…

Monday Apr 12, 2021 - 1:02 pm

XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Files First Order for Rapid COVID Test Kits Amid European Regulatory Approval

Bioscience technology accelerator XPhyto Therapeutics Corp. recently announced it had placed its first order for its Covid-ID Lab rapid, portable virus test from its German development partnerXPhyto received approval for the test kit last month from European regulators with oversight of in vitro diagnostic device (CE-IVD) use certification and the internationally agreed-on ISO 13485 medical product quality standardsThe Covid-ID Lab is designed to help beleaguered…

Tuesday Apr 06, 2021 - 1:23 pm

Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) Completes Pre-Clinical Studies, Progresses Two Drug Candidates

Cybin has completed more than 20 pre-clinical studies in record time.Company is advancing two new therapeutic candidates with enhanced, improved properties.Drug candidates are designed to treat serious psychiatric conditions with high unmet medical needs. Cybin (NEO: CYBN) (OTCQB: CLXPF), a leading biotech company focused on progressing psychedelic therapeutics, has completed key research studies both in vitro and in vivo. The company recently announced that it had completed its…

Monday Mar 29, 2021 - 11:53 am

Pure Extracts Technologies Corp. (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ) Orders First Functional Mushroom Shipment for Global E-Commerce Portal

PULL expands into EU through initial sale of cannabis oil extracts to German pharmaceutical companySale to Germany expected to pave way for additional supply agreements throughout EuropeCompany orders first shipment of functional mushroom products for direct-to-consumer e-commerce portal, expects $15,000 gross monthly sales for each formulationPULL’s new state-of-the-art facility constructed to EU GMP standards for worldwide exports With a focus on the cannabis, hemp, functional…

Articles

Articles Category: Psychedelics

Get Started with InvestorWire

Press Distribution

Explore Press Distribution Solutions

Discover Add-on Solutions